1 Dementia	Primary Care/HSCPs	Mental Health	Acute/ Specialist services		
Comment: Also see NHS FV Guideline for the use of Cognitive Enhancing Drugs (intranet only)					
Due to significant cost-differences standard tablets/capsules are proordispersible tablets or a liquid should be considered instead.	eferred unless u	nable to swallow	/. In which case,		
Rivastigmine patches are relatively expensive and should only be p formulations.	rescribed in pati	ents who canno	t take oral		
Anticholinesterases	Anticholinesterases				
Mild to Moderate					
Donepezil (1st line)	+	✓	+		
Rivastigmine (2 nd line) (for patches preferred brand is Alzest [®])	+	✓	\$		
Galantamine (3 rd line)	\$	✓	+		
Dopaminergic Drugs					
Moderate to Severe	Moderate to Severe				
Memantine	\$	✓	\$		

2. Epilepsy and other Seizure Disorders	Primary Care/CHPs	Acute/ Specialist services
---	----------------------	----------------------------------

Comment: Refer to NICE guideline NG 217 Epilepsies in children, young people and adults

SIGN guideline No 143 Diagnosis and Management of Epilepsy in Adults

MHRA Guidance – Valproate use by Women and Girls

Anti-epileptics

Comment: The MHRA have divided anti-epileptic drugs into 3 categories in order to determine whether it is necessary to maintain continuity of supply of specific manufacturer's products.

The categories relate only to the treatment of epilepsy, it does not apply to the use of these drugs for other indications e.g. mood stabilisation, neuropathic pain.

Cat. 1 - Maintain on specific manufacturer's products

Cat. 2 – May be OK to prescribe as a generic. Need for continued supply of a particular manufacturer's product should be based on clinical judgement and consultation with patient and/or carer. Taking into account factors such as seizure frequency and treatment history. Medicines specified with a specific brand in the list below must be prescribed by brand name only.

Cat. 3 - Usually unnecessary to ensure patients are maintained on a specific manufacturer's product unless specific patient reason e.g. patient anxiety and risk of confusion or dosing errors.

If a patient has to be maintained on a particular product this should be prescribed by brand name or the name of the manufacturer should be stated on the prescription.

In order to maintain continuity of supply, when a specified product is unavailable, pharmacists may dispense a product from a different manufacturer if discussed and agreed with both the prescriber and patient/carer.

For further information on use of generic anti-epileptic drugs in patients with epilepsy see the <u>Specialist Pharmacy Services Guide</u>

Preterred	1st line choice anti-epileptics		
Cat. 1	Carbamazepine (Tegretol® Prolonged Release)	+	✓
	:: Tegretol® Prolonged Release is the preferred tablet formulation for epilepstandard generic tablets are preferred.	sy patients. For	patients withou
Cat. 2	Lamotrigine	+	✓
Cat. 3	Levetiracetam	+	✓
Cat. 2	Sodium valproate	+	✓
Sodiu otherSodiu	y restricted indications: m valproate/valproate salts will remain formulary for male patients for the tre epilepsy, mania and bipolar disorder. m valproate/valproate salts shall only be prescribed for (female) adults who or children for the treatment of generalized, partial or other epilepsy.		
 Any r mania salts f 	new initiation for other indications for (female) adults who have the ability to a and bipolar disorder will be non formulary across NHS Forth Valley. Access for new patients of child bearing age for these indications will be via the IPTI escribing of valproate in patients of child bearing potential should follow the	s to sodium valp R process.	proate/valproate
Cat. 2	Topiramate (preferred formulation is tablets rather than sprinkle capsules)	\$	✓
Adjunctiv	e Therapy in Patients Refractory to 1st line treatment		
Cat. 3	Brivaracetam	+	✓
	Cannabidiol (Epidyolex®)		✓
	Cenobamate (Ontozry®)	+	✓
Comment	:: Cenobamate is the preferred 2 nd line adjunctive therapy in patients with re	sistant epilepsy	
Cat. 2	Clobazam (SLS requirements – only to be prescribed for epilepsy)	+	✓
Cat. 2	Clonazepam	+	✓
Cat. 3	Ethosuximide	+	✓
Cat. 3	Lacosamide	+	✓
Cat. 2	Oxcarbazepine	+	✓
Cat. 1	Phenobarbital	\$	✓
Cat. 1	Phenytoin (Phenytoin Sodium Flynn Pharma)	+	✓
Comment tablets.	:: Due to differences in bioavailability all new patients should be prescribed	phenytoin caps	ules rather than
Cat. 2	Rufinamide (Inovelon®) (For restricted use in Lennox–Gastaut Syndrome)	•	✓
Cat. 2	Zonisamide	+	√
2.1 Statu	s Epilepticus		
	Lorazepam i.v. (1st line)		✓
	Phenytoin i.v. (2 nd line)		✓
Comment	:: Refer to Guideline for the In-Hospital Drug Treatment of Convulsive Status	Epilepticus in A	Adults
	Diazepam (Diazemuls® injection, diazepam rectal tubes)	✓	✓
	Midazolam oromucosal solution (Buccolam®) (Must be prescribed by brand)	+	✓
		1	1

Comment: While Buccolam® is only licensed in paediatrics, the New Drugs & Formulary Group supports the use of Buccolam® in all new patients including adults

3 Menta	al Health Disorders	Primary Care/HSCPs	Mental Health/Substance Misuse	Acute/ Specialist services
3.1 Anxie	ety			
reserved Refer to (t: All sedative hypnotics and anxiolytics are licensed for short courses to alleviate acute conditions after ca Guidance on Benzodiazepines: Prescribing and Mana elf-help resources for patients can be accessed via the	usal factors have agement of Depe	e been established. endence in Primary Ca	
	Diazepam (Long-acting) (due to risk of misuse 10mg tablets are non-formulary and should not be prescribed)	*	1	*
	Lorazepam (Short-acting)	✓	✓	✓
	tt: Lorazepam - Short term use only. Shorter acting control but they carry a greater risk of withdrawal symptom		e preferred in patients	s with hepatic
	Propranolol (standard tablets)	✓	✓	✓
Commen of a PAC	t: Pregabalin is not SMC approved for use in General S2 form.	Anxiety Disorde	er. Requires submission	on and approval
3.2 Atter	ntion deficit hyperactivity disorder			
Commen and mana	t: For further guidance refer to NICE NG87 March 20 agement	18 <u>Attention defi</u>	cit hyperactivity disord	der: diagnosis
CNS Stin	nulants			
formulation (preferred	enidate (1st line) (standard tablets, modified release ons) I modified release brand for tablets is Xaggitin® XL, ed release capsules Equasym® XL, Medikinet® XL)	+	*	+
Commen release p	t: Modified release formulations of methylphenidate s rofiles	hould be prescri	bed by brand name d	ue to different
Lisdexam	fetamine (Elvanse®) (2 nd line)	\$	✓	+
Dexamfet	tamine (3 rd line)	\$	✓	+
Non-stimulants				
	ine (2 nd line for ADHD, may be used 1 st line in some vith co-morbidities)	+	✓	\$
	ne (Intuniv [®]) (3 rd line for ADHD, may be used 2 nd me patients with co-morbidities. Off-label use in	\$	✓	\$
Clonidine disorder)	(Used off-label for adult patients with ADHD and tic	+	✓	\$

Adjunctive treatments for Neurodevelopmental Disorders				
Comment: Fu	rther self-help resources for patients can be accessed v	ria the Mental He	ealth and Wellbe	eing site
Melatonin Imm Melatonin Mod If swallowing of Preso 1-5m If patient unab Adaflex® is cor Melat For children ur solution sugar Melat	cribe melatonin tablets as brand Adaflex® (available in	+	•	*
 Melatonin capsules are expensive and not licensed for use in children. Adaflex® tablets can be crushed and mixed with water directly before administration. Adaflex® will disperse in water in about 1 minute. If needed, Adaflex® can be mixed with juice to aid administration. For children under the age of 6 years old, the use of melatonin 1mg/1ml oral solution sugar free is off label. Many brands of melatonin solution are considered unsuitable for use in children under the age of 6 years old due to their excipient content. For children under the age of 6 years old, prescribe as Melatonin (Consilient Health Ltd) Oral Solution Sugar Free 1mg/ml, as this product has the most favorable excipient profile for use in younger children. The use of crushed melatonin M/R tablets in patients with swallowing problems is not supported. 				
Chloral hydrate	e solution + sleep hygiene measures (paediatrics)	+	✓	✓
3.3 Bipolar d	isorder and mania			
Comment: For patients with a diagnosis of Bipolar disorder also refer to Physical Health Guideline for Patients with Significant Mental Health Problems For further information see NICE CG 185 Bipolar disorder: assessment and management Lithium (1st line) (Priadel® is the preferred lithium brand				
	new patients)			·
when prescribi	thium products Priadel [®] and Camcolit [®] have different bi ing. Liquid preparations Priadel [®] and Li-Liquid [®] also ha <u>sline for the Management of patients on Lithium</u> (intrane	ve different bioa		nust be specified
Ca	arbamazepine	+	✓	
La	motrigine		✓	+
So	dium valproate	\$	✓	+
Va	lproate Semisodium (Syonelle®)	+	✓	\$
Comment: /	All prescribing of valoroate in nationts of child bearing of	stantial abould for	allow the MHDA	quidonos

Comment: All prescribing of valproate in patients of child bearing potential should follow the MHRA guidance Formulary restricted indications:

- Sodium valproate/valproate salts remain formulary for male patients for the treatment of mania and bipolar disorder.
- Any new initiation for females who have the ability to bear children is considered non formulary across NHS Forth Valley. Access to sodium valproate/valproate salts for patients of child bearing potential should be approved via the local IPTR process.

See relevant sections below for the use of sodium valproate/valproate salts for other indications

3.4 Depression			
Comment: Also refer to FV Guidance on Treatment of Depression (in Further self-help resources for patients can be accessed via the Forth		Health and Wel	lbeing site
Monoamine-oxidase Inhibitors			
Moclobemide	+	✓	+
Selective Serotonin Re-uptake Inhibitors			
Citalopram	✓	✓	✓
Fluoxetine (preferred formulation is 20mg capsules)	✓	✓	✓
Sertraline	✓	✓	✓
Serotonin and Noradrenaline Re-uptake Inhibitors			
Duloxetine (30mg, 60mg capsules)	✓	✓	✓
Venlafaxine	✓	✓	✓
Serotonin Uptake Inhibitors			
Trazodone	✓	✓	✓
Tetracyclic Antidepressants			
Mirtazapine	✓	✓	✓
Tricyclic Antidepressants			
Clomipramine	✓	✓	✓
Lofepramine	✓	✓	✓
3.6 Psychoses and schizophrenia			
Antipsychotics			
Comment: Also refer to -			
 Prescribing Guidelines on Depots (intranet only) Physical health guideline for patients with significant mental h 	ealth problem	IS	
For the treatment of patients with delirium please refer to the			
Prescribing an antipsychotic for delirium can be initiated in Pr	imary Care or	in Acute where	the Scottish
delirium association pathway is followedWhere a patient has previously been initiated on an antipsych	notic by Menta	al Health service	s and the natient
has become non compliant, it would be reasonable for Prima			
First Generation			
Chlorpromazine	+	✓	✓
Haloperidol (Baseline ECG Required)	+	✓	✓
Zuclopenthixol Dihydrochloride (Clopixol® tabs)	+	✓	+
Zuclopenthixol Acetate (Clopixol Acuphase®) - for use in an Emergency inpatient environment only		√	
First Generation – Depot Injections			
Flore anticol December 15:	•	✓	+
Flupentixol Decanoate Inj	Ψ	Y	Ψ

Zuclopenthixol Decanoate (Clopixol®) Inj	+	✓	+
Second Generation			
Amisulpride	+	✓	+
Aripiprazole	\$	✓	+
Clozapine (Clozaril®)		✓	+
Comment: Clozapine used for treatment resistant schizophrenia only.			
Olanzapine (preferred formulation is standard tablets)	+	✓	+
Quetiapine (preferred formulary formulation is standard release, not M/R)	\$	√	+
Risperidone (preferred formulation is standard tablets)	+	✓	+
Second Generation – Depot Injections			
Aripiprazole Inj	 	✓	+
Paliperidone Inj	\$	✓	+
Risperidone Inj	+	✓	

4. Movement Disorders	Primary Care/HSCPs	Acute/ Specialist services	
4.1 Dystonias and other involuntary movements			
Essential tremor, chorea, tics and related disorders			
Essential Tremors			
Propranolol (1st line)	✓	✓	
Primidone (2nd line)	+	✓	
Monoamine Depleting Drugs			
Tetrabenazine	+	✓	
Muscle Relaxants			
Botulinum Toxin Type A (Xeomin®, Botox®)		✓	
4.2 Parkinson's Disease			
Comment: Also see – Forth Valley Guidance Prescribing in Parkinson's Disease and Related Connil by mouth NICE Clinical Guideline 71 - Parkinson's Disease in adults	nditions: Nausea/vomitin	ng, agitation and	
Antimuscarinics			
Procyclidine (1st line)	+	✓	
Trihexiphenidyl hydrochloride (2 nd line)	+	✓	
Dopaminergic Drugs	Dopaminergic Drugs		
COM-T Inhibitors			
Entacapone (1st line)	+	✓	

Opicapone (2 nd line)	\$	✓
Dopamine Precursors		
Co-beneldopa (Madopar®)	+	✓
Co-careldopa	+	✓
Levodopa + Carbidopa + Entacapone (Stanek®)	+	✓
Dopamine Receptor Agonists		
Ropinirole (MR tablets (Ipinnia XL®) (1st line)	+	✓
Pramipexole (std. tablets, MR tablets (Pipexus®) (2 nd line)	+	✓
Rotigotine Patch (Neupro®)	+	✓
Comment: To ensure the correct strength of pramipexole is prescribed/dispensed.	Always prescribe	as the base.
MAO-B Inhibitors		
Rasagaline	•	✓
Advanced Therapies	- 1	
Apomorphine	+	✓
Co-careldopa intestinal gel (Duodopa®)		✓
Dyskinesias		
Amantadine	+	✓
Hypersalivation		
Botulinum Toxin Type A (Xeomin®)		✓
Glycopyrronium bromide (Sialanar® oral solution, tablets - off-label use)	+	✓
Comment: Xeomin [®] is SMC approved for the symptomatic treatment of chronic sianeurological disorders in adults	lorrhoea (severe d	drooling) due to
Sialanar is SMC approved for the symptomatic treatment of severe sialorrhoea in characters and older with chronic neurological disorders.	nildren and adoles	scents aged 3
Orthostatic Hypotension		
Midrodine (1st line)	\$	✓
Fludrocortisone (2 nd line) (off-label use)	+	✓
Restless Leg Syndrome		
Ropinirole (1st line) [std. tablets, M/R tablets (Ipinnia XL®)]	✓	✓
Pramipexole (2 nd line) [std. tablets, M/R tablets (Pipexus®)]	✓	✓
Rotigotine Patch (Neupro®)	✓	✓
Comment: Patients with Restless Leg Syndrome (RLS) can initially be managed in information on management see NICE CKS - Restless legs syndrome The use of M/R pramipexole, M/R ropinorole in RLS is an off-label use but may be to attents.	·	

5. Nausea and Labyrinth Disorders	Primary Care/HSCPs	Acute/ Specialist Services
-----------------------------------	-----------------------	----------------------------------

Comment: Choose the correct antiemetic based on the likely cause of the symptoms

For further advice also see -

West of Scotland Cancer Network (WoSCAN) Guideline for Managing Chemotherapy Induced Nausea & Vomiting in Adults https://www.intranet.woscan.scot.nhs.uk/guidelines-and-protocols/supportive-care/ (intranet only)
https://www.intranet.woscan.scot.nhs.uk/guidelines-and-protocols/supportive-care/ (intranet only)
https://www.intranet.woscan.scot.nhs.uk/guidelines-and-protocols/supportive-care/ (intranet only)

Forth Valley Guidance Prescribing in Parkinson's Disease and Related Conditions: Nausea/vomiting, agitation and nil by mouth

Antiemetics and Antinauseants Antihistamines Cyclizine **Dopamine Receptor Antagonists** Metoclopramide (1st line) Domperidone (2nd line) **Neurokinin Receptor Antagonists** To be prescribed in line with Aprepitant WoSCAN guideline Serotonin (5HT₃) Receptor Antagonists Ondansetron (1st line) (preferred formulations are standard tablets, film tablets) Granisetron (2nd line) **Sedating Antihistamines** Cinnarizine **Antimuscarinics** Hyoscine hydrobromide **Antipsychotics - First Generation** Prochlorperazine (1st line) Comment: Prochlorperazine buccal tablets are relatively expensive compared to std. tablets. Only use when std. tablets are unsuitable Droperidol (post-operative prevention and treatment) Haloperidol (2nd line) (palliative care) Levomepromazine (3rd line) (palliative care) Comment: Haloperidol tablets or levomepromazine tablets should only be prescribed if initiated by a Specialist. Haloperidol injections or levomepromazine injections can be initiated in Primary Care for palliative care patients 5.1 Ménière's Disease **Histamine Analogues** Betahistine Comment: Betahistine tablets are only licensed for Ménière's Disease and should not be prescribed for other vestibular disorders. Requires initiation/recommendation by a specialist

6 Pain	Primary Care	Acute/ Specialist Services
Comment: Also refer to		

Scottish Palliative Care Guidelines and Scottish Palliative Care Guidelines on Choosing and Changing Opioids Guidance on Pain Management in a Person with a Substance Misuse Problem (In-Patient) (intranet only) Guideline for Headache Management in Adults						
Analgesics						
Non-Opioid						
	Paracetamol (preferred formulations tablets, caplets) ✓ ✓					

Opioids

Comment: To calculate equivalent doses of different opioids refer to the <u>opioids co</u> <u>Chronic Pain Education Group website</u>		
There is a higher risk or serotonin syndrome when opioids especially tramadol, tap antidepressants. For further information refer to UKMi Medicines Q & A What is the which medicines cause it?	entadol are co-p erisk of serotonin	rescribed with a syndrome and
Weak opioids		
Co-codamol 8/500, 15/500, 30/500	✓	✓
(preferred formulations tablets, caplets)		
Comment: Increased opioid side-effects and risk of dependence with co-codamol.		
Effervescent preparations of compound analgesics may contain high levels of sodi	ım.	
Comment: Codeine should only be used to relieve acute moderate pain in children cannot be relieved by other painkillers such as paracetamol or ibuprofen alone.	n older than 12 y	ears and only if it
A significant risk of serious and life-threatening adverse reactions has been identification appropriate and provided code after tonsillectomy or adenoidectomy (or both). Code children younger than 18 years who undergo these procedures for obstructive sleep	eine is now contr	
Buprenorphine patches (Prescribe by brand – preferred FV brand is Butec® (7 day patch) 5mcg,10mcg,15mcg, 20mcg	✓	✓
Dihydrocodeine	✓	✓
Strong opioids		
prescribing/dispensing errors. Preferred brands are stated in the Formulary under i Short acting opioids should be avoided for breakthrough pain in chronic non maligned To calculate equivalent doses of different opioids refer to the opioids convertor on the Education Group website Also refer to Scottish Palliative Care Guidelines and Scottish Palliative Care Guidelines Opioids	ant pain he <u>West of Scotl</u>	
Morphine- (1st line)	✓	✓
(For M/R products. Prescribe by brand – preferred FV brand is Zomorph®)		
 Comment: Actimorph® oro-dispersible tablets are approved for use in palliative ca Unable to measure liquid doses for low doses of morphine sulphate OR Unable to swallow tablets and measure out the liquid for higher doses 	are patients, who	are:-
Oxycodone (2 nd line, Prescribe by brand – preferred FV brands are: Short acting Shortec [®] , Long acting Longtec [®])	✓	4
Comment: No advantage in using oxycodone over morphine in stage 1-3 renal in It should be noted that oxycodone is twice as potent as morphine. And when switch converted appropriately.	•	dose should be
Alfentanil injection 500mcg/1ml vials (3 rd line)	•	✓
Comment: When prescribing alfentanil for palliative care patients only the 500mcg Higher strength products are used as infusions.	/1ml vials should	be prescribed.
Fentanyl Patch (3 rd line)	✓	✓
(Prescribe by brand – preferred FV brand is Matrifen®)		
Fentanyl buccal tablets (Effentora®)	+	✓
Fentanyl nasal spray (Instanyl®, Pecfent®)	•	✓
Comment: Fentanyl patches are indicated for 3 rd line use for patients with severe difficulties or intractable nausea and vomiting.	pain who have s	wallowing

Fentanyl nasal spray/buccal tablets should only be prescribed for incident pain in cancer patients where short acting opioids are unsuitable. Also refer to Scottish Palliative Care Guidelines and Scottish Palliative Care Guidelines on Choosing and Changing **Opioids** Tapentadol M/R tablets (Tadomon® Prolonged-release tablets) (3rd line) Comment: Standard tablets of tapentadol should not be prescribed. Only M/R formulations of tapentadol are recommended for use by the SMC and only to be prescribed if recommended by a pain specialist. Cyclimorph® inj. Diamorphine inj. 6.1 Headache 6.1a Migraine Comment: Also see local treatment guidelines - Guideline for Headache Management in Adults Step 1 - Non-Steroidal Anti-inflammatory Drugs Aspirin (1st line) Ibuprofen (2nd line) Naproxen (2nd line) Step 2 - Triptans Sumatriptan (1st line) Frovatriptan (2nd line) ✓ Rizatriptan (2nd line) Step 3 - Oral calcitonin gene-related peptide (CGRP) receptor antagonist Rimegepant (Vydura®) **Anti-emetics** Prochlorperazine (1st line) Metoclopramide (2nd line) **Migraine Prophylaxis** Propranolol (1st line) Oral Amitriptyline (2nd line) Candesartan (3rd line) Topiramate (3rd line) Injection (to be used after failure of at least 3 oral migraine prophylaxis drugs above) ✓ Botulinum toxin type A (Botox®) (1st line) Erenumab (Aimovig®) (2nd line) Galcanezumab (Emgality®) 6.2 Neuropathic Pain Comment: Gabapentin and pregabalin have been reclassified as Schedule 3 CDs due to the risk of potential misuse

and links to drug related deaths.

medicines u	nigher risk or serotonin syndrome when antidepressants used for neuropathic pain are coused for depression. For further information refer to UKMi Medicines Q & A What is the risk and which medicines cause it?		
А	Amitriptyline (1st line)	✓	✓
D	Ouloxetine (30mg, 60mg capsules) (2 nd line)	✓	✓
G	Sabapentin (2 nd line)	✓	✓
Comment: doses	For gabapentin more cost-effective to prescribe capsules rather than tablets formulations	s at equiv	alent
N	Nortriptyline (2 nd line) (preferred formulation is tablets)	✓	✓
Р	Pregabalin (2 nd line)	✓	✓
С	Capsaicin cream 0.025% (Zacin®), 0.075% (Axsain®)	✓	✓
(F	Please be aware this is currently unavailable until June 2026)		
C	Capsaicin 179mg (8%) patch (Qutenza®)		✓
	Capsaicin patches are approved for restricted use for peripheral neuropathic pain in non plied within a clinic setting and are relatively expensive	-diabetics	s. They
Trigemina	al Neuralgia		
С	Carbamazepine (standard tablets)	√	✓

7 Sleep Disorders	Primary Care/HSCPs	Mental Health/Substance Misuse	Acute/ Specialist services
7.1 Insomnia			
Hypnotics and anxiolytics			
Comment: Further self-help resources for patients can be	accessed via the M	ental Health and Wellt	peing site
Zopiclone (1 st line) + sleep hygiene measures	✓	✓	✓
Temazepam (2 nd line) + sleep hygiene measures	✓	✓	✓
Zolpidem (2 nd line) + sleep hygiene measures	✓	✓	✓
Melatonin M/R 2mg tablets + sleep hygiene measures	✓	✓	✓
Promethazine + sleep hygiene measures	✓	✓	✓

Comment: Melatonin M/R 2mg tablets are licensed for insomnia in adults over the age of 55 (maximum of 13 weeks) and also for insomnia in adults with learning disabilities.

Use for sleep disorders in children is an off label use and should be initiated by a specialist.

For the use of melatonin in ADHD and other neurodevelopmental disorders refer to section 3.2.

8 Substance Dependence	Primary Care/HSCPs	Mental Health/Substance Misuse	Acute/ Specialist services
8.1 Alcohol dependence			
Comment: For further advice see- Alcohol Dependence -In-patient Management of Alcohol Withdrawal			

	endence – Maintenance of Abstinence			
Ac	amprosate	+	✓	\$
Ch	nlordiazepoxide	+	✓	✓
Dis	sulfiram	+	✓	\$
8.2 Nicotine	e dependence			
(P	Patches - Nicotinell® 1st line, NiQuitin® CQ 2nd ne, Gums, lozenges - Nicotinell®)	√	✓	*
Va	arenicline	✓	✓	✓
Naltrexone f	Also refer to Opiate Replacement Therapy President Maintenance of Opiate Abstinence (intranet o	nly)	ntranet only)	
GP Prescrib	ing Service for Opioid Substitution Therapy (intra	anet only)		1
	uprenorphine (Espranor®) (Substance Use ervices)	\$	✓	+
	uprenorphine Inj. (Buvidal [®]) (For use by ubstance Use Services only)		✓	
		✓	✓	
М	ethadone 1mg/ml mixture	1	•	+
	ethadone 1mg/ml mixture Sugar-free methadone should only be prescribed		•	•
Comment:	•		•	+
Comment:	Sugar-free methadone should only be prescribed altrexone (Substance Use Services)		ts	
Comment: No.	Sugar-free methadone should only be prescribed altrexone (Substance Use Services)		ts	